FDA to review Genzyme's Lemtrada resubmission

PARIS Fri May 30, 2014 2:30am EDT

PARIS May 30 (Reuters) - Sanofi said on Friday the U.S. Food and Drug Administration had agreed to review Genzyme's resubmission of its application for its Lemtrada drug for the treatment of relapsing forms of multiple sclerosis.

A six-month review period has been assigned for the Lemtrada resubmission and Genzyme expects an FDA action in the fourth quarter, Sanofi said in a statement. (Reporting by Dominique Vidalon)

A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article